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Incidence of Tuberculosis in HIV-Infected Patients Before
and After Starting Combined Antiretroviral Therapy in 8
Sub-Saharan African HIV Programs
Sarala Nicholas, MSc,* Kalpana Sabapathy, MSc, MRCP, MBBS,† Cecilia Ferreyra, MD,k
Francis Varaine, MD,‡ and Mar Pujades-Rodr´ ıguez, PhD, MSc, DTMIH, MD,* for the AIDS
Working Group of Me ´decins Sans Frontie `res
Setting: Eight HIV programs in sub-Saharan Africa.
Objective: To describe the incidence of pulmonary and extrapulmonary
tuberculosis before and after the start of combined antiretroviral therapy
(ART) and investigate associated risk factors.
Design: Multicohort study. Adults enrolled between January 2006
and September 2008.
Results: A total of 30,134 patients contributed 25,916 person-years
of follow-up. The incidence of tuberculosis was 10.5 per 100 person-
years during the pre-ART and 5.4 during the ART period. For all
types of tuberculosis, incidence was similar in the pre-ART period
and initial 3 months of ART but declined over time receiving ART
(from 13 per 100 person-years in the ﬁrst 3 months to 1.5 per 100
person-years after 12 months of therapy). Throughout follow-up,
rates of pulmonary tuberculosis remained 2-fold to 3-fold higher than
extrapulmonary tuberculosis rates. Smear-negative pulmonary tuber-
culosis was higher than smear-positive incidence and varied greatly
across sites during the pre-ART period. Incidence was lower in rural
sites, women, patients without prior history of tuberculosis, body
mass index $18.5 kg/m
2, and $200 nadir CD4 cells per microliter.
Recurrence rate was 1.7 per 100 person-years (95% conﬁdence
interval: 1.0 to 2.8).
Conclusions: Our ﬁndings show the high burden that tuberculosis
represents for HIV programs and highlight the importance of earlier
ART start and the need to implement intensiﬁed tuberculosis ﬁnding,
isoniazide prophylaxis, and infection control.
Key Words: combined antiretroviral therapy, cohort studies, HIV,
incidence, tuberculosis
(J Acquir Immune Deﬁc Syndr 2011;57:311–318)
INTRODUCTION
Tuberculosis is a common cause of morbidity and
mortality in patients infected with HIV living in resource-
limited countries. In 2009, 22.5 million people were estimated
to be living with HIV in sub-Saharan Africa.
1 Furthermore,
during the same year, 2.8 million new cases of tuberculosis
were reported in Africa, the majority in the sub-Saharan area;
and 37% of tuberculosis episodes were diagnosed among HIV-
infected patients.
2 The World Health Organization recom-
mends initiating combined antiretroviral therapy (ART) in all
patients coinfected with HIV and tuberculosis.
3 Despite the
existence of affordable medications, too few coinfected
patients receive adequate treatment for both diseases in
Africa, and this situation leads to substantial avoidable
morbidity and mortality.
1
HIV infection increases the risk of developing tubercu-
losis but also modiﬁes the clinical presentation of the disease.
4
HIV-infected patients are twice as likely to experience sputum
smear–negative pulmonary tuberculosis (PTB) than HIV-un-
infected patients,
5 and extrapulmonary tuberculosis (EPTB) is
also more common in HIV-positive patients.
5,6 This contributes
to delayed tuberculosis diagnosis, leads to high mortality, and
represents an important burden for health systems.
Quantifying the burden that different types of tubercu-
losis represent for HIV programs during the pre-ARTand ART
periods is important for program managers. Better under-
standing of factors associated with incident tuberculosis could
help to improve service provision. Previous studies have
provided evidence of the decreased risk of tuberculosis in HIV-
infected patients who initiate ART.
7–15 However, a few studies
have examined rates of smear-positive and smear-negative
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factors in HIV programs.
Me ´decins Sans Frontie `res (MSF) has provided free ART
in resource-limited countries since 2001. In recent years, great
efforts have been made to integrate tuberculosis diagnosis and
treatment into HIV care. The objective of this analysis was to
describe the incidence of smear-positive and smear-negative
PTB and EPTB during pre-ARTand ART periods in large HIV
programs not routinely providing isoniazid prophylaxis in sub-
Saharan Africa and to identify individual-level factors associ-
ated with incident tuberculosis.
MATERIALS AND METHODS
Sites and Cohort Selection
We analyzed data from all MSF-supported HIV
programs in sub-Saharan Africa that had started providing
care to patients coinfected with HIV and tuberculosis before
January 2006, routinely collected information on tuberculosis
episodes in the follow-up and care of HIVinfections and AIDS
(FUCHIA) database (Epicentre; Paris, France), had treated
more than 100 patients with tuberculosis, and had less than
10% of data inconsistencies (eg, discrepancies in the number
of tuberculosis episodes and dates of diagnosis between the
follow-up and tuberculosis questionnaires completed for each
patient or record of new tuberculosis cases for patients who
received retreatement tuberculosis regimens) and missing data
for key tuberculosis-related information (eg, tuberculosis site
location, type of tuberculosis, or results of smear microscopy
for PTB cases).
All programs were located in areas where the annual
tuberculosis incidence rate in the general population exceeded
200 cases per 100,000 population.
16 Asymptomatic HIV-
infected patientswere seen every 6 monthsduring the pre-ART
periodand every 3monthsafter the start of ART. As previously
described,
8 all patients who presented for a pre-ART or ART
consultation with respiratory symptoms for 2 weeks or more
were routinely screened with microscopy of 3 sputum smears
for acid-fast bacilli. PTB was diagnosed in patients with
symptoms or signs suggestive of tuberculosis such as fever,
night sweats, weight loss, chest radiographic ﬁndings (where
available), and/or lack of response to at least one course of
antibiotics. Results of sputum microscopy for acid-fast bacilli
determined whether the diagnosis was smear positive or
negative. Diagnosis of EPTB was based on the presence of
clinical signs or symptoms suggestive of systemic and site-
speciﬁc tuberculosis (eg, lymphadenopathy, meningism) and
radiological, biochemistry, or microscopic ﬁndings. Culture of
Mycobacterium tuberculosis was not routinely available in the
programs. Patients with CD4 cell count ,200 cells per
microliter and those with clinical HIV stage 4 were eligible for
ART.
17 Isoniazid prophylaxis was not provided to patients.
Data Collection and Deﬁnitions
In agreement with health ministries, at each consultation
or hospitalization, individual patient data were prospectively
collected using standardized forms and entered into the
FUCHIA database. Data collected included sex, age, history
and diagnosis of tuberculosis, type of tuberculosis episode,
dates of appointment and clinical visits, CD4 cell count
measurements, and date of ART start. No patient identiﬁers
were kept in the datasets analyzed.
Patients with incident tuberculosis were those who were
diagnosed after 15 days of program inclusion (or 15 days after
ART start for analysis during the ART period), given the low
proportion of patients diagnosed with smear-positive PTB
(32.5%) and the time necessary to diagnose smear-negative
PTB and EPTB in the programs.
18 Because in immunocom-
promised patients, tuberculosis treatment is often initiated
rapidly after tuberculosis diagnosis but ART start is delayed
for several weeks to maximize treatment adherence and until
clinical stabilization of the patient is achieved, patients who
initiated ART within 2 months of enrollment and started
tuberculosis treatment between enrollment and ART initiation
were considered prevalent tuberculosis cases in the pre-ART
analysis. Patients who were diagnosed with tuberculosis
during the pre-ART period and then started ARTwere included
in the ARTanalysis. Recurrence was deﬁned as a tuberculosis
episode diagnosed during follow-up, at least 3 months after
tuberculosis treatment completion.
Study Population
All HIV-infected adults who entered the programs from
January 1, 2006, to September 30, 2008, were eligible for
inclusion. Those with prevalent tuberculosis at program entry
(n = 3354, 8.3%) or with less than 15 days of follow-up
(n = 6865, 18.6%) were excluded.
Statistical Analysis
Patient follow-up was divided into pre-ART (between
15 days after program entry and up to 15 days after ART start)
and ART (from 16 days of ART start) periods. For patients
started on therapy, we further split time on ART into ,3, 3–5,
6–11, and $12 months. All analyses were performed
separately for the pre-ART and ART periods. For each period
considered, we right censored follow-up at dates of ﬁrst
diagnosed tuberculosis episode, death, transfer, last visit, or
end of the appropriate period. Patients with less than 3 months
of follow-up during the pre-ART period were excluded from
pre-ART analyses (83.5% of these had started ART and 8%
died or were lost to follow-up within this period).
To investigate associations between incident tubercu-
losis and programmatic and individual-level factors, we used
random effects Poisson models, assuming a gamma distri-
bution for the random parameter, which accounted for
potential intraprogram variation. Factors considered were
type of treatment site (urban or rural), sex, calendar year at
ARTinitiation or program enrollment (2006 and 2007–2008),
age (as a continuous variable), prior history of ARTuse (naive
or experienced), body mass index (BMI: ,18.5, $18.5
kg/m
2, and missing
19), nadir CD4 cell count (,50, 50–99,
100–199, $200 cells/mL, and missing), time since ART start,
and prior tuberculosis history (recorded history of tuberculosis
at program entry, patients with tuberculosis relapse, failure or
treated after defaulting). Backward stepwise procedure using
P . 0.10 for variable exclusion and log-likelihood ratio tests for
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nadir CD4 cell count by initial CD4 cell counts and restricting
the analyses to the subset of patients with available CD4 and
BMI information were also performed. All analyses were
performed using Stata 10 (StataCorp LP, College Station, TX).
RESULTS
The 8 HIV programs included were located in 6 African
countries, 4 in urban sites, and 4 in rural sites (Table 1). Between
January 2006 and September 2008, a total of 40,353 adults
entered the programs. After excluding 3354 patients who
presented with tuberculosis at program entry and 6865 with
,15 days of follow-up in the program (including 401 deaths and
1894 lost to follow-up), we analyzed information from 8998
patients with $3 months of pre-ART follow-up and 19,325
patients with .15 days of follow-up on ART (Fig. 1). A total of
7754 person-years [median follow-up = 9.0 months; interquartile
range (IQR) 6.0–14.3 months] of pre-ART and 18,162 person-
years (median follow-up = 10.6 months, IQR 4.4–17.7 months)
of ART follow-up were analyzed. At program inclusion, median
age was 34 years, 65.9% of patients were women, and 3.0% were
ART experienced (Table 2). Fourteen percent were in World
Health Organization stage 4, and median CD4 cell count was 196
cells per microliter. At the end of the study follow-up, 2646
patients had died and 1944 were lost to follow-up.
Tuberculosis Pre-ART
Nine percent (n = 780) of the 8998 patients who were
included in the pre-ART analysis were diagnosed with
tuberculosis. Tuberculosis incidence was 10.5 per 100
person-years [95% conﬁdence interval (CI): 9.8 to 11.3] but
ranged from 4.4 per 100 person-years to 47.0 per 100
person-years (see Table, Supplemental Digital Content 1,
http://links.lww.com/QAI/A161). It was slightly higher in
patients with lower levels of nadir CD4 cell counts (Fig. 2).
Seventy-four percent of tuberculosis episodes diagnosed
were pulmonary, ranging from 52.9% to 91.7% across sites.
Incidence of PTB was 7.8 per 100 person-years (95% CI: 7.2 to
8.4; see Figure A, Supplemental Digital Content 4,
http://links.lww.com/QAI/A164) and ranged from 3.2 to 41.8
per 100 person-years (Fig. 3A). Eighty-one percent of patients
with PTB (470 of 581) had available bacteriological results, and
155 (33.0%) of them were smear positive. Incidence of smear-
positive PTB was 2.0 per 100 person-years (95% CI: 1.7 to 2.4;
see Figure B, Supplemental Digital Content 4,
http//links.lww.com/QAI/A164) and this was similar across sites
(Fig. 3C). Incidence of smear-negative PTB was 4.1 per 100
person-years (95% CI: 3.7 to 4.6) and ranged from 1.9 to 31.0 per
100 person-years (Fig. 3D). Seventy-eight percent of patients
diagnosedwithsmear-negativePTB (247of315) hadradiological
ﬁndings suggestive of PTB. Overall rate of EPTB was 2.6 per 100
person-years (95% CI: 2.3 to 3.0; see Table, Supplemental
Digital Content 1, http://links.lww.com/QAI/A161) and varied
from 1.2 to 7.8 per 100 person-years across programs (Fig. 3B).
Tuberculosis During ART
Five percent (n = 933) of the 19,325 patients included in
the ART analysis were diagnosed with tuberculosis. Almost half
of thesewere diagnosed within the ﬁrst 3 months of ART (50.4%)
and 91.7% within the ﬁrst year of therapy. Tuberculosis incidence
was 5.4 per 100 person-years (95% CI: 5.0 to 5.7) and ranged
from 3.0 to 10.6 per 100 person-years (see Table, Supplemental
Digital Content 2, http://links.lww.com/QAI/A162). Incidence
decreased with increasing levels of nadir CD4 cell counts (Fig. 2).
Among the 19 patients who started second-line ART, no
tuberculosis episodes were diagnosed after regimen switch
[median time of follow-up on second line was 6.9 months
(IQR 4.7–12.3)].
Incidence of PTB was 3.7 (95% CI: 3.5 to 4.0) per 100
person-years (see Figure A, Supplemental Digital Content 4,
http://links.lww.com/QAI/A164). Eighty-two percent of patients
with PTB (544 of 660) had available bacteriological results, and
250 (46.0%) of them were smear positive. Rates of smear-positive
and smear-negative PTB were 1.4 per 100 person-years (95% CI:
1.2 to 1.6) and 1.6 per 100 person-years (95% CI: 1.5 to 1.8),
respectively (see Figure B, Supplemental Digital Content 4,
http://links.lww.com/QAI/A164), and similar across programs
(Figs. 3C, D). Seventy-six percent of patients diagnosed with
smear-negative PTB (223 of 294) had radiological ﬁndings
suggestive of PTB. Overall incidence of EPTB was 1.5 (95% CI:
1.4 to 1.7) and similar across sites (see Figure A, Supplemental
TABLE 1. Characteristics of ART Sites, Numbers of Patients, and Duration of Follow-up
Site Country Location
Tuberculosis Cases
Per 100,000*
Type
of Site
No.
Adults
Pre-ART
Period
ART
Period
Enrolled
ART
Started
No.
Adults
No.
Person-years
No.
Adults
No.
Person-years
1 Guinea—Conakry Conakry 287 Urban 3451 2163 1011 819 1974 1494
2 Guinea—Conakry Gueckedou 287 Urban 1072 681 319 259 637 455
3 Kenya Mathare 353 Urban 1077 664 404 356 633 636
4 Malawi Chiradzulu 346 Rural 10,028 6190 3827 3265 5623 4534
5 Malawi Thyolo 346 Rural 5033 4655 275 203 4378 4714
6 Mozambique Alto Mae 431 Rural 3771 3426 439 425 3290 3604
7 Nigeria Lagos 311 Urban 808 713 86 64 691 941
8 Uganda Arua 330 Rural 4894 2234 2637 2363 2099 1783
Total 30,134 20,726 8998 7754 19,325 18,162
*2009 World Health Organization Report on Global Tuberculosis Control.
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of tuberculosis decreased markedly with time on ART, from
13.0 per 100 person-years (95% CI: 11.9 to 14.2) in the 0 to 3
month period to 1.5 per 100 person-years (95% CI: 1.2 to 1.9)
in the $12-month period after ART start (see Table, Supple-
mental Digital Content 3, http://links.lww.com/QAI/A163).
Both PTB and EPTB incidence decreased after ART
initiation, but rates of PTB remained 2-fold to 3-fold higher
over time (see Figure A, Supplemental Digital Content 4,
http://links.lww.com/QAI/A164).
Factors Associated With Incident Tuberculosis
Incidence of tuberculosis during the ART period was
lower in patients treated in rural than in urban sites [adjusted
FIGURE 1. Study proﬁle. A total of
2646 deaths were recorded: 328
patients (9.8%) with prevalent tu-
berculosis at program entry, 401
patients (5.8%) with ,15 days of
follow-up in the program, and 1917
patients (72.4%) eligible for study
inclusion (1348 ART patients and
569 non–ART patients). A total of
1944 patients lost to follow-up were
recorded: 23 patients (0.7%) with
prevalent tuberculosis at program
entry, 1894 patients (97.4%) with
,15 days of follow-up in the pro-
gram, and 27 patients (1.4%) eligi-
ble for study inclusion (1 ART patient
and 26 non–ART patients).
TABLE 2. Patient Characteristics at Enrollment and at ART Initiation, 2006–2008
Pre-ART Analysis ART Analysis*
Excluded (n = 21,136)
Included
n = 8998
Non–ART Patients ART Patients Included Excluded
n = 3477 n = 17,659 n = 19,325 n = 1401
Calendar year (%)
2006 4006 (44.5) 860 (24.7) 6735 (38.1) 6746 (34.9) 224 (16.0)
2007 4552 (50.6) 1136 (32.7) 7616 (43.1) 8943 (46.3) 295 (21.1)
2008 440 (4.9) 1481 (42.6) 3308 (18.7) 3636 (18.8) 882 (63.0)
Sex (%)
Women 6557 (72.9) 2165 (62.3) 11,133 (63.0) 12,411 (64.2) 838 (59.8)
Age group (y)
Median (IQR) 32.9 (27.0–40.0) 32.0 (27.0–40.0) 35.0 (29.0–42.0) 35.0 (29.1–42.1) 34.5 (29.1–42.0)
Prior history of ART use (%)
ART experienced 28 (0.3) 7 (0.2) 859 (4.9) 874 (4.5) 5 (0.4)
Prior history of tuberculosis (%)
Yes 221 (2.5) 132 (3.8) 931 (5.3) 1697 (8.8) 96 (6.9)
Clinical stage (%) n = 8262 n = 3265 n = 16,536 n = 18,427 n = 1322
1 or 2 5646 (68.3) 1769 (54.2) 4970 (30.1) 5313 (28.8) 473 (35.8)
3 2253 (27.3) 1135 (34.8) 8331 (50.4) 9116 (49.5) 508 (38.4)
4 363 (4.4) 361 (11.1) 3235 (19.6) 3998 (21.7) 341 (25.8)
BMI (%), kg/m
2 n = 8868 n = 3302 n = 16,582 n = 18,293 n = 1297
,18.5 2188 (24.7) 1206 (36.5) 6414 (38.7) 6227 (34.0) 578 (44.6)
$18.5 6680 (75.3) 2096 (63.5) 10,168 (61.3) 12,066 (66.0) 719 (55.4)
Median (IQR) 20.3 (18.5–22.3) 19.5 (17.5–21.6) 19.4 (17.4–21.5) 19.7 (17.7–21.8) 18.9 (16.9–21.0)
CD4 cell count (cells/mL) n = 6937 n = 2579 n = 14,503 n = 15,666 n = 1118
Median count (IQR) 398 (286–567) 331.0 (158.0–505.0) 132.0 (63.0–203.0) 142 (70–213) 132 (58–204)
Nadir CD4 cell count (cells/mL) n = 8553 n = 2613 n = 14,463 n = 17,514 n = 1170
Median nadir (IQR) 332 (222–488) 331.0 (156.0–505.0) 131.0 (62.0–202.0) 150 (74–225) 134 (60–210)
*Among ART patients only.
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T a b l e3 ] .R a t e sw e r el o w e ri nw o m e n( a I R R0 . 8 2 ,9 5 %C I :
0.71 to 0.94), patients who started therapy in later calendar
years (aIRR 0.82, 95% CI: 0.72 to 0.94 for 2007–2008
compared to 2006), and in those with BMI $18.5 kg/m
2
(aIRR 0.51, 95% CI: 0.45 to 0.59).
Individuals with nadir CD4 cell count .100 cells per
microliter also had lower tuberculosis rates (aIRR 0.84, 95%
CI: 0.69 to 1.01 for 100–199; and 0.70, 95% CI: 0.57 to 0.87
for $200; compared with ,50 cells/mL). However, patients
with prior history of tuberculosis were more likely to be
diagnosed with tuberculosis after ART start (aIRR 1.28, 95%
CI: 1.05 to 1.55). Incidence rate ratios of tuberculosis
decreased with time on therapy (from 0.48, 95% CI: 0.41 to
0.57,for the 3-to5-monthperiod, to0.12, 95%CI:0.09to0.15
for the $12-month period, compared with the ,3-month
period after ART start). Results of risk factor analysis for
incident tuberculosis during the pre-ART period weregenerally
similar to those for the ART period, but the association with
calendar yearwasnotstatisticallysigniﬁcant(P=0.63),andthe
sizeofeffect washigher for nadirCD4counts[aIRR0.44(95%
CI: 0.33 to 0.59) for 100–199 and 0.15 (95% CI: 0.11 to 0.19)
for $200 compared with ,50 cells/mL].
Adjusted estimates from sensitivity analyses replacing
nadir CD4 by initial CD4 cell counts did not differ except for
the smaller magnitude of the estimates observed for initial
CD4 count data (data not shown). Results of the risk factor
analysis excluding patients with missing CD4 count and BMI
data were also similar to those presented here, except for the
observed stronger protective effect that having a history of
ARTuse at therapy start had (aIRR 0.46, 95% CI: 0.27 to 0.78)
and the lower incidence rate ratio for prior history of
tuberculosis (aIRR 1.67, 95% CI: 1.21 to 2.30) during the
pre-ART period.
Tuberculosis Recurrence
Of the 1010 patients diagnosed with tuberculosis during
the study period and who remained in care for at least 3
months after completing tuberculosis treatment, 15 (1.5%) had
recurrent tuberculosis. Median duration between treatment
completion and recurrence was 5.4 months (IQR 4.0–8.1).
Overall recurrence rate was 1.7 per 100 person-years (95% CI:
1.0 to 2.8). At 6 months of tuberculosis treatment completion,
recurrence rate was 1.7 per 100 person-years (95% CI: 0.8 to
3.4). Median age at time of diagnosis was 37.9 years. Sixty
percent were women, and 80.0% were receiving ART at the
time of recurrence. For 93.3% of patients, the previous
tuberculosis episode was pulmonary and 40.0% of these were
smear positive. Sixty-seven percent of recurrences were
pulmonary, and 70.0% of these were smear positive.
DISCUSSION
In these large HIV programs in Africa, we observed high
incidences of tuberculosis during the pre-ART and ART
periods, 10.5 and 5.4 per 100 person-years, respectively.
Incidence of all types of tuberculosis was similar during the
pre-ART and initial 3 months of ART use and markedly
decreased with time receiving ART. Rates of smear-negative
PTB were higher than of smear-positive PTB.
The observed high incidence of tuberculosis during
the pre-ART and initial 3 months of ART periods, and
higher incidence in patients with lower CD4 count levels,
reﬂects the high prevalence of tuberculosis in Africa
20 and
the increased risk of disease in immunocompromised
patients. Overall estimates during the ART period corre-
spond closely to those from previous studies in resource-
limited countries, with reported rates ranging from 2.4 to
10.5 per 100 person-years.
11,13 However, the rates are
approximately 2-fold lower than those reported in a South
African community survey where culture, chest radiology,
and cytological examinations were performed.
12 As access
to these diagnostic tools is often limited in our programs, it
is likely that some patients with tuberculosis remain
undiagnosed or are diagnosed late. In our cohorts, we ob-
served a decrease in tuberculosis incidence of 88% between
the initial 3 months of therapy and the period after the ﬁrst
year of treatment. Some of the patients diagnosed during
the ﬁrst months of ART are likely to represent initially
undiagnosed cases of tuberculosis, whereas others may
have immune reconstitution inﬂammatory syndrome.
21–25
Incidence of both types of tuberculosis declined with
duration of ART, but PTB rates remained higher over time (7.8
and 2.6 per 100 person-years for PTB and EPTB in the pre-ART
phase and 3.7 and 1.5 per 100 person-years, respectively, in the
ART phase). These rates are lower than those reported in other
settings,
12,26 which might be related to underdiagnosis in our sites
due to passive tuberculosis case detection and diagnostic
limitations. The protective effect observed over time on ART is
similar to what has been described elsewhere.
12 Approximately 1
of 3 patients diagnosed with PTB in our study had smear-positive
tuberculosis, which is the most infectious form of the disease.
We identiﬁed several factors associated with incidence
of tuberculosis in both the pre-ARTand ART periods. Patients
attending rural clinics had a 42% lower risk of being diagnosed
with tuberculosis. This likely reﬂects disparities in diagnostic
capacity rather than differences in tuberculosis exposure because
FIGURE 2. Incidence of tuberculosis before and after ART
initiation by nadir CD4 count level, 2006–2008.
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2006–2008
Pre-ART Period ART Period
No.
Incident
Cases
No.
Person-
years of
Follow-up
Incidence
Per 100
Person-
years
(95% CI)
IRR
No.
Incident
Cases
No.
Person-
years of
Follow-up
Incidence
Per 100
Person-
years
(95% CI)
IRR
Unadjusted
(95% CI)
Adjusted
(95% CI)
Unadjusted
(95% CI)
Adjusted
(95% CI)
Type of setting P = 0.005 P = 0.004 P = 0.010 P = 0.021
Urban 283 1358 20.8 (18.5
to
23.4)
1.00 1.00 275 3297 8.3 (7.4 to
9.4)
1.00 1.00
Rural 497 6040 8.2 (7.5
to
9.0)
0.39 (0.20 to
0.76)
0.37 (0.22 to
0.63)
658 14116 4.7 (4.3 to
5.0)
0.60 (0.41 to
0.88)
0.58 (0.39 to
0.86)
Individual factors*
Calendar year P = 0.629 P , 0.001 P = 0.004
2006 467 4159 11.2 (10.3
to
12.3)
1.00 — 448 9569 4.7 (4.3 to
5.1)
1.00 1.00
2007–2008 313 3239 9.7 (8.6
to
10.8)
0.96 (0.83 to
1.12)
— 485 7843 6.2 (5.7 to
6.8)
1.27 (1.12 to
1.45)
0.82 (0.72 to
0.94)
Sex P , 0.001 P = 0.004 P , 0.001 P=0.004
Men 294 1870 15.7 (14.0
to
17.6)
1.00 1.00 368 5932 6.2 (5.6 to
6.9)
1.00 1.00
Women 486 5528 8.8 (8.0
to
9.6)
0.62 (0.53 to
0.72)
0.80 (0.69 to
0.93)
565 11,480 4.9 (4.5 to
5.3)
0.79 (0.69 to
0.90)
0.82 (0.71 to
0.94)
Age (y)†
—— —
P = 0.162
—— — —
P = 0.087 P = 0.068
1.01 (1.00 to
1.01)
0.99 (0.99 to
1.00)
0.99 (0.99 to
1.00)
Prior history of ART use P = 0.522 P = 0.001 P = 0.067
ART naive 777 7379 10.5 (9.8
to
11.3)
1.00 — 905 16,458 5.5 (5.2 to
5.9)
1.00 1.00
ART experienced 3 19 15.5 (5.0
to
48.2)
0.68 (0.21 to
2.20)
— 28 955 2.9 (2.0 to
4.2)
0.53 (0.36 to
0.78)
0.71 (0.48 to
1.04)
Prior tuberculosis history P , 0.0001 P , 0.001 P=0.002 P = 0.018
No 722 7249 10.0 (9.3
to
10.7)
1.00 1.00 815 15,947 5.1 (4.8 to
5.5)
1.00 1.00
Yes 58 149 38.9 (30.0
to
50.3)
3.12 (2.37 to
4.09)
1.88 (1.42 to
2.47)
118 1465 8.1 (6.7 to
9.6)
1.38 (1.13 to
1.67)
1.28 (1.05 to
1.55)
BMI (kg/m
2) P , 0.001 P , 0.001 P , 0.001 P , 0.001
,18.5 362 1536 23.6 (21.3
to
26.1)
1.00 1.00 436 5260 8.3 (7.5 to
9.1)
1.00 1.00
$18.5 406 5777 7.0 (6.4
to
7.7)
0.29 (0.25 to
0.33)
0.36 (0.31 to
0.42)
465 11,249 4.1 (3.8 to
4.5)
0.47 (0.41 to
0.53)
0.51 (0.45 to
0.59)
Nadir CD4 count (cells/mL) P , 0.001 P , 0.001 P , 0.001 P , 0.001
,50 59 98 60.2 (46.6
to
77.7)
1.00 1.00 182 2660 6.8 (5.9 to
7.9)
1.00 1.00
50–99 68 170 40.1 (31.6
to
50.9)
0.68 (0.48 to
0.97)
0.63 (0.44 to
0.90)
174 2614 6.7 (5.7 to
7.7)
1.00 (0.81 to
1.23)
1.13 (0.92 to
1.40)
316 | www.jaids.com q 2011 Lippincott Williams & Wilkins
Nicholas et al J Acquir Immune Deﬁc Syndr   Volume 57, Number 4, August 1, 2011rates of smear-positive PTB were similar across sites.
Furthermore, women had rates 18% lower than men. This
ﬁnding is consistent with results fromprevious studies
8,9,12,16 and
could be explained by differences in susceptibility to either
infection or reactivation of infection, exposure, reporting of
symptoms of disease, or the later presentation of men compared
with women in the course of HIV disease. Studies conducted in
resource-limited settings have reported that men frequently seek
HIV care at a more advanced stage of disease than women.
27,28
We observedthattuberculosisincidencewas 49%lowerin
patients with normal BMI than in malnourished adults. Poor
nutritional status is known to be a risk factor for tuberculosis
development,
10,13,29,30 and weight loss is a common consequence
of tuberculosis. Tuberculosis incidencewas also lowerin patients
less severely immunosuppressed, and rates of all forms of
tuberculosis decreased with time since the start of ART. These
ﬁndings are consistentwith previous research
9,11–13 and highlight
the importance of early ART initiation in HIV-infected patients
TABLE 3. (continued) Associations Between Site- and Individual-Level Factors and Incident Tuberculosis Before and After ART Initiation,
2006–2008
Pre-ART Period ART Period
No.
Incident
Cases
No.
Person-
years of
Follow-up
Incidence
Per 100
Person-
years
(95% CI)
IRR
No.
Incident
Cases
No.
Person-
years of
Follow-up
Incidence
Per 100
Person-
years
(95% CI)
IRR
Unadjusted
(95% CI)
Adjusted
(95% CI)
Unadjusted
(95% CI)
Adjusted
(95% CI)
100–199 162 732 22.1 (19
to
25.8)
0.41 (0.30 to
0.56)
0.44 (0.33 to
0.59)
267 5513 4.8 (4.3 to
5.5)
0.70 (0.58 to
0.84)
0.84 (0.69 to
1.01)
$200 398 6180 6.4 (5.8 to
7.1)
0.12 (0.09 to
0.16)
0.15 (0.11 to
0.19)
196 5361 3.7 (3.2 to
4.2)
0.57 (0.46 to
0.70)
0.70 (0.57 to
0.87)
Time since ART start (mo) P , 0.001 P , 0.001
,3 — — — — — 470 3619 13.0 (11.9 to
14.2)
1.00 1.00
3–5 — — — — — 215 3530 6.1 (5.3 to
7.0)
0.47 (0.40 to
0.55)
0.48 (0.41 to
0.57)
6–11 — — — — — 171 5211 3.3 (2.8 to
3.8)
0.25 (0.21 to
0.30)
0.26 (0.22 to
0.31)
$12 — — — — — 77 5053 1.5 (1.2 to
1.9)
0.12 (0.09 to
0.15)
0.12 (0.09 to
0.15)
*Factors measured at program entry for the pre-ART analysis and at ART start for the ART analysis.
†Age estimates per unit change.
ART, combined antiretroviral therapy; IRR, incidence rate ratio.
FIGURE 3. Incidence of tuberculosis
before and after ART initiation by site
and type of disease, 2006–2008.
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tuberculosis and other opportunistic infections.
Patients with prior history of tuberculosis had rates of
tuberculosis 28% higher than other patients, and 6-month
recurrence rate was 1.7 per 100 person-years. This is
consistent with ﬁndings from other studies reporting rates
1.46–4.73 higher in patients previously treated for tubercu-
losis
14,26,31 but differ from those published by Lawn et al
12 who
found no evidence of association between recorded history of
tuberculosis and incident disease.
The main strengths of our analysis were large sample size,
study of various types of tuberculosis during both pre-ART and
ART periods, and homogeneity in care provision (including
criteria for ART initiation and types of antiretroviral regimens
provided) and data collection tools used across programs.
Although the quality and success of tuberculosis diagnosis and
case ﬁnding varied across sites and over time, especially for
EPTB and smear-negative PTB, cohort heterogeneity was
accounted for in the analysis and calendar year was included
as one of thevariables in the risk factor analysis. Median duration
of follow-up in the programs was relatively short, limiting the
time for study of risk factors on late-stage forms of tuberculosis.
Despite the number of patientswith missing nadir CD4 count and
BMI information (5% and 1%, respectively, in the pre-ART
analysis and 9% and 5%, respectively, in the ART analysis),
sensitivity analyses restricted to the subgroup of patients with
available information support the conclusions of the article.
CONCLUSIONS
Our ﬁndings highlight the high burden that tuberculosis
represents for HIV programs in Africa and the importance of
earlier HIV diagnosis and treatment, and support calls for
implementing the 3 I’s of tuberculosis control: intensiﬁed case
ﬁnding, isoniazid prophylaxis, and infection control.
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